Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 0: clinchem.2006.067645v1, 2006; 10.1373/clinchem.2006.067645
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2006.067645v1
52/6/1021    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Blesa, S.
Right arrow Articles by Chaves, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Blesa, S.
Right arrow Articles by Chaves, F. J.

Received on January 27, 2006
Accepted on March 24, 2006

Molecular Diagnostics and Genetics

Analysis of Sequence Variations in the LDL Receptor Gene in Spain: General Gene Screening or Search for Specific Alterations?

Sebastian Blesa 1, Ana Barbara Garcia-Garcia 1, Sergio Martinez-Hervas 2, Maria Luisa Mansego 1, Veronica Gonzalez-Albert 1, Juan Francisco Ascaso 2, Rafael Carmena 2, Jose Tomas Real 2, Felipe Javier Chaves 1*

1 Laboratorio de Estudios Geneticos, Fundacion de Investigacion HCUV, Hospital Clinico Universitario de Valencia, Valencia, Spain
2 Service of Endocrinology and Nutrition, Hospital Clinico Universitario de Valencia, University of Valencia, Valencia, Spain

* To whom correspondence should be addressed. E-mail: felipe.chaves{at}uv.es.

Background: Familial hypercholesterolemia (FH) is a frequent form of autosomal-dominant hypercholesterolemia that predisposes to premature coronary atherosclerosis. FH is caused by sequence variations in the gene coding for the LDL receptor (LDLR). This gene has a wide spectrum of sequence variations, and genetic diagnosis can be performed by 2 strategies.

Methods: Point variations and large rearrangements were screened along all the LDLR gene (promoter, exons, and flanking intron sequences).

Results: We screened a sample of 129 FH probands from the Valencian Community, Spain, and identified 54 different LDLR sequence variations. The most frequent (10% of cases) was 111insA, and 60% of the variants had a frequency as low as 1%. A previously described method for detection of known sequence variations in the Spanish population by DNA array analysis allowed the identification of only ~50% of patients with a variant LDLR gene and ~40% of the screened samples.

Conclusion: Our results indicate that the adequate procedure to identify LDLR sequence variations in outbreed populations should include screening of the entire gene.




The following articles in journals at HighWire Press have cited this article:


Home page
J Am Coll CardiolHome page
G. P. Jarvik, J. D. Brunzell, and A. G. Motulsky
Frequent Detection of Familial Hypercholesterolemia Mutations in Familial Combined Hyperlipidemia
J. Am. Coll. Cardiol., November 4, 2008; 52(19): 1554 - 1556.
[Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. Blesa, S. Vernia, A.-B. Garcia-Garcia, S. Martinez-Hervas, C. Ivorra, V. Gonzalez-Albert, J. F. Ascaso, J. C. Martin-Escudero, J. T. Real, R. Carmena, et al.
A New PCSK9 Gene Promoter Variant Affects Gene Expression and Causes Autosomal Dominant Hypercholesterolemia
J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3577 - 3583.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
D. Tejedor, S. Castillo, P. Mozas, E. Jimenez, M. Lopez, M. T. Tejedor, M. Artieda, R. Alonso, P. Mata, L. Simon, et al.
Comparison of DNA Array Platform vs DNA Sequencing as Genetic Diagnosis Tools for Familial Hypercholesterolemia.
Clin. Chem., October 1, 2006; 52(10): 1971 - 1972.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the American Association for Clinical Chemistry.